Wells Fargo & Company Xenon Pharmaceuticals Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 59,067 shares of XENE stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,067
Previous 61,457
3.89%
Holding current value
$2.41 Million
Previous $2.65 Million
12.93%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding XENE
# of Institutions
220Shares Held
69.6MCall Options Held
59.7KPut Options Held
60.7K-
Avoro Capital Advisors LLC New York, NY5.67MShares$231 Million3.02% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.42MShares$180 Million1.86% of portfolio
-
Wellington Management Group LLP Boston, MA3.83MShares$156 Million0.03% of portfolio
-
Commodore Capital LP New York, NY2.75MShares$112 Million9.63% of portfolio
-
Capital World Investors Los Angeles, CA2.68MShares$110 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.54B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...